Literature DB >> 8070220

Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

R Donnelly1, H L Elliott, P A Meredith.   

Abstract

Although individualised antihypertensive therapy is widely recommended, prospective methods for optimising treatment are hampered by the paucity of basic information about dose-plasma concentration-response relationships for commonly used drugs. Concentration-effect analysis has been applied to a number of therapeutic areas. With antihypertensive drugs this approach has clearly identified direct relationships between pharmacokinetic and pharmacodynamic profiles within individual patients. Thus, either a linear or nonlinear model can be used to quantify the antihypertensive drug response in terms of parameters that incorporate pharmacokinetic and pharmacodynamic information. Furthermore, these models take account of placebo effects and time-dependent changes in blood pressure and drug concentrations during a dosage interval. Concentration-effect analysis has been used to characterise the responses to a range of calcium antagonist drugs. These studies have demonstrated that these analyses are useful for optimising dosage schedules, identifying determinants of blood pressure response, and predicting steady-state profiles of blood pressure (including peak/trough effects) after administration of a single ('test') dose. This mode of analysis warrants early inclusion in the clinical development of any new antihypertensive agent, so that the familiar difficulties in identifying the optimum dosage range are avoided.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070220     DOI: 10.2165/00003088-199426060-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  52 in total

1.  Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Authors:  G Mikus; V Mast; C Fischer; C Machleidt; U Kuhlmann; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  The modelling of drug response.

Authors:  B Whiting; A W Kelman
Journal:  Clin Sci (Lond)       Date:  1980-11       Impact factor: 6.124

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

4.  Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.

Authors:  D R Abernethy; J Gutkowska; L M Winterbottom
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

5.  Combination of nifedipine and doxazosin in essential hypertension.

Authors:  R Donnelly; H L Elliott; P A Meredith; C A Howie; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1992-04       Impact factor: 3.105

Review 6.  Clinical pharmacokinetics of amlodipine.

Authors:  P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

7.  Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls.

Authors:  F M Gengo; S C Fagan; G Krol; H Bernhard
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

8.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

9.  The place of the calcium antagonist verapamil in antihypertensive therapy.

Authors:  F R Bühler; U L Hulthén; W Kiowski; F B Müller; P Bolli
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  An evaluation of the pharmacodynamics and pharmacokinetics of nicardipine combined with enalapril in essential hypertension.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1987-12       Impact factor: 3.105

View more
  4 in total

1.  Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.

Authors:  Chantal Csajka; Thierry Buclin; Karin Fattinger; Hans R Brunner; Jérôme Biollaz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

3.  Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib.

Authors:  Hongrui Liu; Yiqun Yu; Lu Liu; Chunyan Wang; Nan Guo; Xiaojuan Wang; Xiaoqiang Xiang; Bing Han
Journal:  Front Pharmacol       Date:  2022-08-26       Impact factor: 5.988

4.  Cardiovascular Safety Assessment in Early-Phase Clinical Studies: A Meta-Analytical Comparison of Exposure-Response Models.

Authors:  D J Conrado; D Chen; W S Denney
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.